Siemens Healthineers has now added in its portfolio Corindus CorPath GRX, the only FDA cleared and CE certified robotic system, for coronary and peripheral vascular interventions in India.

With state-of-art technology, the company has opened a new field for advanced therapies business, tapping into adjacent growth markets with great potential for the future.

The robotic cardiovascular interventions can aid significantly in this case, by contributing to cardiovascular medical conditions like heart diseases, where the ideal treatment include complex procedures in the coronary arteries by specialised medical professionals. The smart procedural automation can enable performing complex interventional cases in shorter time, with precision, and with better clinical outcomes.

Adoption of robotics in surgical intervention will provide an enormous impetus to the Indian healthcare sector. Possibilities of remote treatment in the near future (currently under approval) could address the key geographical challenges of limited availability of specialists and corresponding clinical facilities for minimally invasive procedures in many regions. 

With Corindus technology, Siemens Healthineers is well-positioned to be the leading player in the field of robotic vascular interventions.

“The interplay of protection, precision and standardisation through robotic-assisted interventions will allow the cardiologists to perform complex procedures faster and better.  This will allow specialists to improve procedural quality and expand precision medicine; thereby improving clinical outcomes for the patient,” said Sanjay David, Head, Advanced Therapies, Siemens Healthineers, India.